|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03347 TIGERMED
Nominal 
43.980 +2.540 (+6.129%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | -- | -- | 6,603,120 | 7,384,039 | 7,085,471 | 5,213,538 |
| Cost of Sales | -- | -- | -- | -- | (4,300,027) | (2,965,420) |
| Gross Profit | -- | -- | -- | -- | 2,785,444 | 2,248,118 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | (535,709) | 284,672 | (24,575) | (24,426) | |
| Profit / (Loss) on Disposal | -- | -- | 3,563 | (188) | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | -- | -- | 31,271 | 105,183 | 39,763 | 14,348 | |
| Profit / (Loss) before Taxation | -- | -- | 664,462 | 2,488,533 | 2,594,912 | 3,689,502 | |
| Taxation | -- | -- | (216,630) | (338,606) | (313,652) | (292,864) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | -- | -- | (42,688) | (125,077) | (265,174) | (517,539) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 887,890 | 119.154% | 405,143 | 2,024,850 | 2,016,086 | 2,879,099 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | -- | -- | 38,067 | (108,324) | (145,249) | (234,139) |
| Depreciation & Amortisation | -- | -- | 364,036 | 339,023 | 284,844 | 196,762 |
| Directors' Emoluments | -- | -- | 9,192 | 8,929 | 7,871 | 3,487 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 104.000 | 121.277% | 47.000 | 234.000 | 233.000 | 332.000 |
| DPS (cts) | 12.600 | -- | 30.000 | 56.800 | 55.000 | 50.000 |
| Dividend Payout Ratio (%) | 12.115% | -- | 63.830% | 24.274% | 23.605% | 15.060% |
| Cash flow per share ($) | -- | -- | 1.271 | 1.330 | 1.311 | 1.343 |
| NBV per share ($) | -- | -- | 24.000 | 24.102 | 22.499 | 20.844 |
| Remarks: | Real time quote last updated: 01/04/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 887,890 |
| %Change | 119.154% |
| EPS / (LPS) | RMB 1.040 |
| NBV Per Share (¥) | RMB -- |